ETFMG Treatments, Testing and Advancements ETF
GERM
New York Stock Exchange Arca- -
USD
- -
- -
- -
- -
(- -)
Recent
price
- -
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Amplify Treatments, Testing and Advancements ETF (GERM) is an exchange-traded fund that seeks to provide investment results corresponding generally to the total return performance, before fees and expenses, of the Prime Treatments, Testing and Advancements Index. The fund invests in U.S.-listed equity securities or depositary receipts of companies engaged in research, development, commercialization of treatments or vaccines for infectious diseases, as well as biological testing; holdings include biotechnology firms such as Emergent BioSolutions Inc., Enanta Pharmaceuticals Inc., Gilead Sciences Inc., Dynavax Technologies Corp., and BioCryst Pharmaceuticals Inc., with a focus on growth and value stocks across diversified market capitalizations using a modified equal-weighting methodology and quarterly rebalancing. Launched in June 2020 by ETF Managers Group (ETFMG) as part of its thematic ETF lineup targeting biotech advancements in infectious disease subsectors, the ETF was initially domiciled in the United States and primarily targeted institutional and retail investors seeking exposure to vaccines, therapies, and testing technologies. Geographically, the portfolio is concentrated in North America, with nearly all assets in U.S.-based companies operating in the health technology and biotechnology segments. In a major strategic shift, ETFMG entered into a definitive agreement in June 2023 for Amplify ETFs to acquire its ETF lineup, including GERM, which completed in January 2024 and expanded Amplify's assets under management to over $9 billion across 31 funds. Subsequently, Amplify announced the liquidation of GERM along with two other ETFs in August 2024, ceasing creation and redemption orders after August 29, 2024, with trading halting on September 5, 2024, and a liquidating distribution of $19.30 per share paid on September 11, 2024. The ETF, headquartered through its sponsor in Chicago, Illinois, under Amplify ETF Trust, is no longer active as of September 2024.